C

CSL

Develops and delivers biotherapies and vaccines

Hospital Relations Manager Immunology and AOH

Full-Time
No salary listed
Expert
Bachelor's
Paris, France
In PersonThe role covers the Hauts-de-France and Normandy regions.
Sales & Account ManagementField Sales

About the job

Requirements
  • A minimum Bac +3 degree in a commercial and/or scientific field.
  • A medical representative diploma or equivalent certification attested by the AGVM.
  • At least 8–10 years of experience as a hospital representative promoting scientific products in complex environments.
  • Successful experience promoting molecules intended exclusively for hospitals.
  • Deep knowledge of hospital internal processes and the hospital environment.
  • Knowledge of pharmaceutical and hospital regulations and the promotional information charter.
  • Understanding of the competitive environment, specialties, marketing authorizations, packaging, and product use.
  • Scientific and medical knowledge of hospital specialties.
  • Knowledge of hospital prescribing practices.
  • Proficiency in communication, information delivery, negotiation, meeting facilitation, and information transmission techniques.
  • Ability to develop partnerships.
  • Understanding of health economics, including medical economics and pharmacoeconomics.
  • Proficiency in sales techniques.
  • Ability to work collaboratively in a team.
  • Proficiency with Microsoft Office and Outlook.
  • Proficiency with the current customer relationship management system and QlikView sales-analysis tool.
  • Technical English proficiency.
Responsibilities
  • Contribute to the quantitative and qualitative objectives of the Immunology and AOH network while supporting proper medicine use in healthcare institutions and complying with internal rules and applicable legislation.
  • Maintain CSL’s image as a preferred partner in its areas of expertise.
  • Own the sales-volume objectives and results for the assigned territory.
  • Develop sales of CSL’s Immunology and AOH product portfolio in the assigned territory.
  • Create favorable conditions for tenders and understand the relevant decision-making process.
  • Ensure execution and follow-up of the territory action plan.
  • Promote CSL products to healthcare professionals.
  • Collaborate transversely with the territory team to implement coordinated actions with healthcare professionals in accordance with the action plan.
  • Develop strong, trusted customer relationships by identifying needs related to CSL’s product and service portfolio.
  • Transmit customer information to management, the territory team, and relevant departments.
  • Establish a list of key hospital customers.
  • Contribute to the development of commercial tactics.
  • Set action priorities for the territory team.
  • Provide healthcare professionals with information about promoted products, CSL’s quality policy, and CSL’s ethical rules.
  • Communicate product information, current indications, safety data, and proper-use information using approved promotional or institutional materials.
  • Communicate CSL ethical rules and inform healthcare professionals of their rights regarding their personal data processed by CSL.
  • Organize face-to-face and remote visits and staff meetings with healthcare professionals in accordance with the rules of the services visited.
  • Prepare, conduct, and facilitate hospital medical-information meetings and organize regional expert meetings with key opinion leaders and other healthcare professionals.
  • Supervise guests and facilitate a booth at regional, national, and international congresses.
  • Maintain the scientific knowledge required for the role by participating in required training and assessments.
  • Follow up, when applicable, on clinical studies established by CSL at centers that are already open.
  • Implement the validated sales tactics from the territory action plan with customers in the assigned territory.
  • Develop the territory action plan, prioritize tactical actions aimed at healthcare professionals, and support product listing in assigned hospitals.
  • Ensure proper medicine use with the pharmacist responsible for plasma-derived medicines.
  • Work actively with the National Sales Director and the regional key account contact for the territory.
  • Propose and manage follow-up of resource allocations required for identified customers.
  • Track and analyze monthly product sales and promptly submit analyses to the National Sales Director using applicable tools.
  • Conduct competitive intelligence and communicate relevant information to the appropriate departments.
  • Understand the decision-making process for treatment selection.
  • Initiate and develop ethical customer relationships in accordance with the promotional information charter.
  • Adapt product and service arguments to the different healthcare professionals visited.
  • Share and reconcile customer data with colleagues and internal departments.
  • Coordinate with internal resources to address customer needs, campaign feedback, new needs, and commitment follow-up.
  • Promptly transmit information collected for pharmacovigilance and quality complaints in accordance with regulatory and internal CSL requirements, as well as questions requiring medical information.
  • Use the customer relationship management system and other tools or processes required by management to share information.
  • Plan and report medical-visit activity, including reports, appointments, and expenses.
  • Follow and apply all communicated internal procedures.
  • Track the investment budget and related activities.
  • Serve as the expert for assigned accounts and customers regarding sales opportunities in the territory.
  • Analyze gaps between objectives and actual results.
  • Analyze and interpret monthly sales data and submit it to management.
  • Propose corrective actions without delay.
Desired Qualifications
  • Knowledge of plasma-derived medicines and recombinant analogues.

About the company

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CSL reported US$176 million FY26 cost savings, ahead of its transformation target.
  • US military flu-vaccine exceptions restored some demand after April 2026 mandate cuts.
  • VarmX’s 2029 coagulation program gives CSL a new high-value pipeline beyond plasma.

What critics are saying

  • FY26 statutory loss hit US$2.6 billion after US$7.1 billion impairments and restructuring.
  • CSL plans US$400 million FY27 savings, implying more closures, layoffs, and execution friction.
  • The U.S. plasma turnaround depends on Horizon 2; failure risks long-term margin collapse.

What makes CSL unique

  • CSL’s FY26 revenue reached US$15.8 billion across plasma, vaccines, and Vifor.
  • Seqirus’ AUJEMFLU won UK and European approvals, backed by Lancet Phase 3 data.
  • HEMGENIX remains Europe’s first approved hemophilia B gene therapy, strengthening CSL Behring.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

1%
PR Newswire
Oct 21st, 2026
CSL appoints ViiV Healthcare chief Deborah Waterhouse as CEO on $1.9M base salary

CSL Limited has appointed Deborah Waterhouse as chief executive officer and managing director, effective February 1, 2027. The board's decision followed a global search and was unanimous. Waterhouse has led ViiV Healthcare, an HIV specialist majority owned by GSK, since 2017. ViiV had sales of £7.7 billion in GSK's 2025 financial year. She also serves as president of GSK Global Health and previously ran GSK's US vaccines and primary care businesses. Her base salary will be £1,500,000 a year. She will stay based in the UK. Gordon Naylor will remain interim chief executive until then, before returning to the board as a non-executive director.

Yahoo Finance
Oct 8th, 2026
CSL to roll out Haemonetics' NexSys devices across all US plasma centres by end of 2027

Haemonetics shares jumped 12% after the company announced CSL now expects to move all of its current US plasma collection centres to Haemonetics' NexSys devices by the end of 2027. The deal, first disclosed in August, was initially limited to only a portion of CSL's US centres with no timeline. The expanded agreement is significant because losing CSL previously flattened Haemonetics' growth. In fiscal 2026, the company's organic revenue growth was just 1.1%, compared to 9.5% excluding lost CSL sales. Following the surge, Haemonetics trades at approximately 21 times forward earnings, above its five-year average of 19.1 times. The deal is non-exclusive with no minimum purchase requirements, meaning CSL can still modify scope and timing. Management plans to provide further details during its November earnings call.

Pharma Dispatch
Oct 6th, 2026
CSL raises $1.5B from US bond investors to refinance debt

CSL has raised US$1.5 billion through corporate bonds issued in the United States to refinance existing debt. The Australian biotechnology company turned to offshore debt markets for the transaction. The bond issuance allows CSL to manage its capital structure by replacing current borrowings with new financing secured from US investors.

CSL
Sep 21st, 2026
CSL partners with VarmX in a strategic collaboration and option agreement to develop first-in-class investigational coagulation treatment

Melbourne, Australia – 16 September 2025 CSL today announced it has entered into a strategic collaboration with privately held Dutch biotech company VarmX BV to support the company’s...

PR Newswire
Sep 10th, 2026
CSL Seqirus' triple-enhanced flu vaccine shows superior protection for older adults in Lancet study

CSL Seqirus has published Phase 3 study results in The Lancet Infectious Diseases for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine for older adults. The vaccine, marketed as AUJEMFLU, combines three proven approaches: MF59 adjuvant, cell-based manufacturing, and higher-dose formulation. The randomised study enrolled 7,699 adults aged 50 and older across eight countries. Results demonstrated superiority versus an adjuvanted egg-based comparator across all four influenza strains and age groups. The vaccine showed non-inferiority versus a recombinant vaccine for three of four strains in the 50-plus age group and all four strains in those aged 65-plus. The trivalent formulation received approval from the UK's MHRA and the European Commission earlier this year for adults aged 50 and above. Regulatory submissions have been made in multiple markets.